Department of Medicine, Division of Geriatrics, NYU Long Island School of Medicine, Mineola, NY.
Department of Medicine, Division of Oncology-Hematology, NYU Long Island School of Medicine, NYU Perlmutter Cancer Center, Mineola, NY.
Clin Lymphoma Myeloma Leuk. 2022 Feb;22(2):76-81. doi: 10.1016/j.clml.2021.08.002. Epub 2021 Aug 12.
Second primary malignancies (SPMs) are long-term complications in cancer survivors. Mucosa-associated lymphoid tissue (MALT) lymphomas are indolent extra-nodal marginal zone lymphomas, the majority of which typically have long-term survival. In this study, we investigated the incidence and pattern of SPMs in adult patients diagnosed with MALT lymphomas between January 2000 and December 2016.
Using the SEER-18 database and multiple primary standardized incidence ratio (MP-SIR) session of SEER stat software for statistical analysis, we assessed SPMs in MALT lymphomas.
During this time, a total of 12,500 cases of MALT lymphomas were diagnosed, of which 1466 patients developed 1626 SPMs (O/E ratio: 1.48, 95% CI:1.41-1.55, P<.001). The median latency period for development of SPMs was 54 months (range 6-201 months). Secondary non-Hodgkin lymphomas, as defined by SEER as distinct from the primary lymphoma, was the most common SPM with 299 cases, followed by lung cancer (O/E ratio: 6.15, 95% CI:5.47-6.89, P<.0001). There were 898 SPMs that developed between 6- 59 months (O/E ratio: 1.47, 95% CI:1.37-1.57, P<.0001) and 728 after 60 months latency (O/E ratio: 1.5, 95% CI:1.39-1.61, P<.0001) after diagnosis of the primary MALT lymphomas. An increased incidence of both solid and hematologic cancers occurred in patients as early as 6 months after diagnosis of MALT lymphoma.
These findings indicate that despite the indolent nature of most MALT lymphomas, there is an increased risk for SPMs warranting long-term follow up.
第二原发恶性肿瘤(SPM)是癌症幸存者的长期并发症。黏膜相关淋巴组织(MALT)淋巴瘤是惰性结外边缘区淋巴瘤,大多数患者有长期生存。本研究旨在调查 2000 年 1 月至 2016 年 12 月期间诊断为 MALT 淋巴瘤的成年患者的 SPM 发生率和模式。
使用 SEER-18 数据库和 SEER stat 软件的多个主要标准化发病比(MP-SIR)会话进行统计分析,评估 MALT 淋巴瘤中的 SPM。
在此期间,共诊断出 12500 例 MALT 淋巴瘤,其中 1466 例患者发生 1626 例 SPM(O/E 比:1.48,95%CI:1.41-1.55,P<.001)。发生 SPM 的中位潜伏期为 54 个月(范围 6-201 个月)。SEER 定义的继发性非霍奇金淋巴瘤与原发性淋巴瘤不同,是最常见的 SPM,有 299 例,其次是肺癌(O/E 比:6.15,95%CI:5.47-6.89,P<.0001)。6-59 个月(O/E 比:1.47,95%CI:1.37-1.57,P<.0001)和 60 个月潜伏期后(O/E 比:1.5,95%CI:1.39-1.61,P<.0001)发生的 SPM 分别有 898 例和 728 例。在诊断出原发性 MALT 淋巴瘤后,患者在 6 个月后即可更早地发生实体癌和血液系统癌症。
这些发现表明,尽管大多数 MALT 淋巴瘤具有惰性特征,但仍存在 SPM 的风险增加,需要长期随访。